This study is currently recruiting

Description: This is a phase 4, multicenter, prospective, observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy (DMD) treatment outcomes in participants receiving eteplirsen, golodirsen, and casimersen in routine clinical practice. Participants in this study will have been prescribed eteplirsen, golodirsen, or casimersen commercially prior to entry into the study.

Eligibility & Criteria

IRB #: IRB00195928

Principal Investigator: Doris Leung, MD, PhD

Eligible Age Range: All

Gender: All

Diagnosis: Duchenne Muscular Dystrophy